Obiltoxaximab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Chimeric (mouse/human) |
| Target | Bacillus anthracis anthrax |
| Clinical data | |
| Trade names | Anthim |
| ATC code | none |
| Identifiers | |
| CAS Number | 1351337-07-9 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6444H9994N1734O2022S44 |
| Molar mass | 145.5 kg/mol |
Obiltoxaximab is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1]
This drug was developed by Elusys Therapeutics, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.